CN118660715A - 用于神经退行性或神经系统疾病或病症的基于粒细胞-巨噬细胞集落刺激因子的治疗 - Google Patents

用于神经退行性或神经系统疾病或病症的基于粒细胞-巨噬细胞集落刺激因子的治疗 Download PDF

Info

Publication number
CN118660715A
CN118660715A CN202380021043.5A CN202380021043A CN118660715A CN 118660715 A CN118660715 A CN 118660715A CN 202380021043 A CN202380021043 A CN 202380021043A CN 118660715 A CN118660715 A CN 118660715A
Authority
CN
China
Prior art keywords
csf
patient
activity
expression
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380021043.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·洛克
I·乔希
T·博伊德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Partner Therapy Ltd
Original Assignee
Partner Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Therapy Ltd filed Critical Partner Therapy Ltd
Publication of CN118660715A publication Critical patent/CN118660715A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380021043.5A 2022-02-11 2023-02-10 用于神经退行性或神经系统疾病或病症的基于粒细胞-巨噬细胞集落刺激因子的治疗 Pending CN118660715A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309220P 2022-02-11 2022-02-11
US63/309,220 2022-02-11
PCT/US2023/062374 WO2023154855A2 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Publications (1)

Publication Number Publication Date
CN118660715A true CN118660715A (zh) 2024-09-17

Family

ID=87565120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380021043.5A Pending CN118660715A (zh) 2022-02-11 2023-02-10 用于神经退行性或神经系统疾病或病症的基于粒细胞-巨噬细胞集落刺激因子的治疗

Country Status (8)

Country Link
US (1) US20250134959A1 (enExample)
EP (1) EP4475874A4 (enExample)
JP (1) JP2025508308A (enExample)
KR (1) KR20240147980A (enExample)
CN (1) CN118660715A (enExample)
AU (1) AU2023219770A1 (enExample)
CA (1) CA3242855A1 (enExample)
WO (1) WO2023154855A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235795A2 (en) * 2022-06-01 2023-12-07 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2025168003A1 (zh) * 2024-02-06 2025-08-14 上海市第四人民医院 一种治疗神经退行性疾病的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2017185085A1 (en) * 2016-04-22 2017-10-26 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP4103618A4 (en) * 2020-02-12 2024-05-01 The Scripps Research Institute LONG-ACTING GM-CSF AND METHODS OF USE

Also Published As

Publication number Publication date
CA3242855A1 (en) 2023-08-17
WO2023154855A2 (en) 2023-08-17
AU2023219770A1 (en) 2024-08-22
US20250134959A1 (en) 2025-05-01
EP4475874A4 (en) 2026-05-13
JP2025508308A (ja) 2025-03-26
KR20240147980A (ko) 2024-10-10
EP4475874A2 (en) 2024-12-18
WO2023154855A3 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
Harari et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
JP2023090751A (ja) 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体
US20100143357A1 (en) Uses of Mammalian Cytokine; Related Reagents
KR102040235B1 (ko) RGMa 결합 단백질 및 그 사용
JP7678802B2 (ja) Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
WO2005079844A2 (en) Use for interleukin-33 (il33) and the il-33 receptor complex
KR19980064719A (ko) 인터로이킨-18-수용체 단백질
KR20060015482A (ko) 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
US20250134959A1 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
JPH06315394A (ja) Ｔｎｆリガンド
HRP20030215A2 (en) Chemokine mutants in the tratment of multiple sclerosis
CN118043672A (zh) 帕金森病的生物标志物
US7919248B2 (en) Methods for the modulation of IL-13
JP2008517998A (ja) 胸腺特異的タンパク質
US20240361339A1 (en) Biomarkers for parkinson's disease
JPH09506243A (ja) レセプター認識因子、蛋白配列およびその使用方法
HRP20030842B1 (hr) UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
EP1740199B1 (en) Il6r/il6 chimera for therapy of chemotherapy-induced peripheral neuropathy
EP3116526B1 (en) Pharmaceutical compositions comprising april for use the treatment of multiple sclerosis, autoimmune encephalitis, neuromyelitis optica, alzheimer disease or parkinson disease
CA2610691C (en) Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases
US20080305078A1 (en) Soluble Il-17Rc Variant and Uses Thereof
EP1581759A2 (en) Methods for treating taxol-induced sensory neuropathy
KR20100132869A (ko) 치료적 이용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination